Form D · Biotechnology
Vaxart, Inc.
San Francisco, CA · CIK 0001480950
Offering snapshot reported Aug 6, 2013 · SEC filing
- Reported sold
- $20M Offering amount: $20M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 24, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 6, 2013 | Initial | $19,999,997 | No comparison | 10 | SEC filing |
| Jun 29, 2012 | Amendment | $16,868,419 | $13,372,311vs Jan 14, 2010 | 11 | SEC filing |
| Jan 14, 2010 | Initial | $3,496,108 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-200797
Series C Preferred Stock, Common Stock issuable upon conversion of Preferred Stock.
Source: Form D, filed Aug 6, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Cornwell | Executive |
| Michael Finney | Director |
| Wouter Latour | Director, Executive |
| Jan Leschly | Director |
| David Liebowitz | Executive |
| David Madden | Executive |
| Richard Markham | Director |
| Sean Tucker | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
20 California Street, 7 Th Floor
San Francisco, CA, 94111
San Francisco, CA, 94111